Patents by Inventor Penglie Zhang

Penglie Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-5 fused rings as C5a inhibitors
    Patent number: 10562896
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: February 18, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • MODULATORS OF CHEMOKINE RECEPTORS
    Publication number: 20200039969
    Abstract: Compounds are provided as chemokine inhibitors having the structure:
    Type: Application
    Filed: May 16, 2019
    Publication date: February 6, 2020
    Inventors: Xi CHEN, Dean R. DRAGOLI, Junfa FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Manmohan Reddy LELETI, Venkat MALI, Jeffrey McMAHON, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • Processes and intermediates in the preparation of C5aR antagonists
    Patent number: 10532982
    Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: January 14, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Jaroslaw Kalisiak, Antoni Krasinski, Rebecca M. Lui, Jay Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-?4?7 integrin blocking antibodies
    Patent number: 10532051
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: January 14, 2020
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Karen Ebsworth, Yu Wang, Yibin Zeng, Penglie Zhang, Joanne Tan
  • Soluble C5aR antagonists
    Patent number: 10487098
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: November 26, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Antoni Krasinski, Venkat Reddy Mali, Shichang Miao, Sreenivas Punna, Yang Song, Valentino J. Stella, Yibin Zeng, Penglie Zhang
  • Substituted tetrahydropyrans as CCR2 modulators
    Patent number: 10464934
    Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: November 5, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Junfa Fan, Jaroslaw Kalisiak, Rebecca M. Lui, Venkat Reddy Mali, Jeffrey P. McMahon, Jay P. Powers, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
    Publication number: 20190300526
    Abstract: The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 3, 2019
    Inventors: Pingchen FAN, Rebecca M. LUI, Rajinder SINGH, Venkat Reddy MALI, Yibin ZENG, Penglie ZHANG
  • AUTOMATIC OPTICAL INSPECTION DEVICE AND METHOD
    Publication number: 20190293566
    Abstract: An automatic optical inspection (AOI) device and method are disclosed. The device is adapted to inspect an object under inspection (OUI) (102) carried on a workpiece stage (101) and includes: a plurality of detectors (111, 112) for capturing images of the OUI (102); a plurality of light sources (121, 122) for illuminating the OUI (102) in different illumination modes; and a synchronization controller (140) signal-coupled to both the plurality of detectors (111, 112) and the plurality of light sources (121, 122).
    Type: Application
    Filed: July 31, 2017
    Publication date: September 26, 2019
    Inventors: Hailiang LU, Junwei JIA, Pengli ZHANG, Hongji ZHOU, Wen XU, Fan WANG
  • 2-oxindole compounds
    Patent number: 10421748
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: September 24, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Manmohan Reddy Leleti, Rebecca M. Lui, Viengkham Malathong, Jay P. Powers, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • INDANE-AMINES AS PD-L1 ANTAGONISTS
    Publication number: 20190282555
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: February 21, 2019
    Publication date: September 19, 2019
    Inventors: Christopher LANGE, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Penglie ZHANG
  • PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
    Publication number: 20190276402
    Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
    Type: Application
    Filed: March 21, 2019
    Publication date: September 12, 2019
    Inventors: Pingchen FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Rebecca M. LUI, Jay POWERS, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG
  • SOLUBLE C5aR ANTAGONISTS
    Publication number: 20190270761
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 5, 2019
    Inventors: Pingchen FAN, Antoni KRASINSKI, Venkat Reddy MALI, Shichang MIAO, Sreenivas PUNNA, Yang SONG, Valentino J. STELLA, Yibin ZENG, Penglie ZHANG
  • Macrocyclic immunomodulators
    Patent number: 10392405
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: August 27, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Viengkham Malathong, Jeffrey McMahon, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Penglie Zhang
  • Inhibitors of CXCR2
    Patent number: 10370363
    Abstract: Compounds are provided as inhibitors of CXCR2, having the structure:
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: August 6, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Viengkham Malathong, Jeffrey McMahon, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang, Venkat Mali
  • METHODS OF TREATING GENERALIZED PUSTULAR PSORIASIS WITH AN ANTAGONIST OF CCR6 OR CXCR2
    Publication number: 20190209527
    Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist.
    Type: Application
    Filed: January 7, 2019
    Publication date: July 11, 2019
    Inventors: James J. CAMPBELL, Karen EBSWORTH, Antoni KRASINSKI, Venkat Reddy MALI, Jeffrey McMAHON, Rajinder SINGH, Ju YANG, Chao YU, Penglie ZHANG
  • Diazole amides
    Patent number: 10342781
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: July 9, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Juan C. Jaen, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Modulators of chemokine receptors
    Patent number: 10336736
    Abstract: Compounds are provided as chemokine inhibitors having the structure:
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: July 2, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Antoni Krasinski, Manmohan Reddy Leleti, Venkat Mali, Jeffrey McMahon, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
    Publication number: 20190194208
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Rajinder SINGH, Yibin ZENG, Penglie ZHANG
  • DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
    Publication number: 20190192491
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Pingchen FAN, Christopher W. LANGE, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • Soluble C5aR antagonists
    Patent number: 10329314
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: June 25, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Antoni Krasinski, Venkat Reddy Mali, Shichang Miao, Sreenivas Punna, Yang Song, Valentino J. Stella, Yibin Zeng, Penglie Zhang